Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.
about
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complexAnti-VEGF single-chain antibody GLAF-1 encoded by oncolytic vaccinia virus significantly enhances antitumor therapyInhibition of VEGF-C modulates distal lymphatic remodeling and secondary metastasisr84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity inductionQuantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imagingVariants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding siteMultimodal microvascular imaging reveals that selective inhibition of class I PI3K is sufficient to induce an antivascular responseEffects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flowFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentAnti-VEGF-A affects the angiogenic properties of tumor-derived microparticlesNotch-dependent VEGFR3 upregulation allows angiogenesis without VEGF-VEGFR2 signallingA humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft modelsStromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+CD11b+ cellsTumor angiogenesisTargeting the vascular endothelial growth factor pathway in the treatment of human malignancy.Ultrasound-enhanced bevacizumab release from echogenic liposomes for inhibition of atheroma progression.Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.Synthetic antibodies as therapeutics.Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancerA Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalingsConditional Müllercell ablation causes independent neuronal and vascular pathologies in a novel transgenic model.Inhibitory effects of anti-VEGF antibody on the growth and angiogenesis of estrogen-induced pituitary prolactinoma in Fischer 344 Rats: animal model of VEGF-targeted therapy for human endocrine tumors.GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer.Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using 111In-bevacizumabIn vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies.Beyond natural antibodies: the power of in vitro display technologies.VEGF blockade decreases the tumor uptake of systemic oncolytic herpes virus but enhances therapeutic efficacy when given after virotherapy.A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis.Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.A Histopathological Study of Multi-hormone Producing Proliferative Lesions in Estrogen-induced Rat Pituitary Prolactinoma.Endosialin expression in side populations in human sarcoma cell lines.Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.Canonical hedgehog signaling augments tumor angiogenesis by induction of VEGF-A in stromal perivascular cellsCharacterization of bevacizumab dose response relationship in U87 brain tumors using magnetic resonance imaging measures of enhancing tumor volume and relative cerebral blood volume.
P2860
Q24293027-62FF20E9-BC8B-4CD1-91CC-F88E459B0CDFQ24655930-60F67EC2-15B0-49E0-BB69-5B1B564D848AQ27311384-4D3391A1-9173-40DF-A145-ABC943194AC6Q27321768-9F821ACE-C65F-4F62-9A4F-7EADE5FD7F9BQ27346895-9A63553A-598B-4B24-91BE-200C344F0A81Q27654214-9D409EED-B47B-4DDD-80D9-6BBB600FFA5CQ28384680-0896BB6E-9CAA-4382-9DEA-D751832FE902Q28477440-E7B66CF5-782B-4833-8A0C-2292608320F0Q28533949-98843257-4654-4225-86A6-06BCDE04EED4Q28538098-58FF89D2-79EC-4A2D-9FCF-8E4B6700C5ACQ28587298-8C86A728-6798-43A5-A6A5-3F9A3AA34372Q28749085-F3E47887-E906-48A3-A138-C1C6FAEDAC08Q28749398-0AF61D27-70D5-43E3-AAAF-024ECA5B1977Q29614938-E5D15D79-548E-4D8E-8CB4-D4B8F5237837Q30358961-E7D23903-85DC-48A4-A8AC-2E2EE9303B7CQ30380799-9BB96E6F-A5D0-4634-9893-5E6FD5840956Q30438696-85FAF914-0DB6-48C1-ADF9-A29894144912Q30474689-E5439497-A47A-4CFC-B4AC-83C3F5515EB1Q33230191-0E94FD46-AF38-426B-9E40-2577B57B22BCQ33265617-E7B3FFD7-EA65-4B40-8436-13A7B2F71D4CQ33401352-B3425453-1BBF-4EE6-9FA3-040337FEC539Q33413979-33964CF3-AA78-4093-B51E-AEEACA66D308Q33557623-07F21279-40ED-4D2A-B8AA-AF0E149AE972Q33581991-2ACA0B46-7675-4315-B8A9-B497CCBB6281Q33591382-4DDE291C-1B9A-4C55-97F2-BE9BC53ADA03Q33645920-F6A339D6-28D0-4658-9D6D-797BB9006694Q33733451-175D6706-B8D6-4E62-87D7-3FB54F8DC08DQ33740232-1EF06AA8-A5AE-4878-A605-83D081DFE31AQ33819576-FB8EB1F2-2C38-430F-A5F6-E327A0092356Q33841864-8C2B1C53-38E8-4675-9A4B-E7494910F677Q33976318-4FD6910E-6554-43C9-A834-0C5383607A29Q33996024-0E898070-780D-4CE9-BBD4-4997E406A84CQ34068174-D8C94F92-C6D4-4452-AB63-AE82CD46524BQ34184494-B7F0B946-96E0-4DA7-BEC2-703046EC4A03Q34319627-81AE5C9F-349E-452D-9276-D7DE39120202Q34455259-413E1B47-57CF-413D-8DBD-6826A7328477Q34497997-7314B14F-4EC4-4243-87EB-8BAC52AC3A0DQ34854858-ED7BC0C9-190B-42C0-9C44-F0553D526F37Q35034972-81670E00-DE63-4ECB-BA34-516678DAA1C1Q35068630-3C7C2E5C-2952-4949-A84B-2AFC6B59F654
P2860
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Cross-species vascular endothe ...... contribution of stromal VEGF.
@ast
Cross-species vascular endothe ...... contribution of stromal VEGF.
@en
type
label
Cross-species vascular endothe ...... contribution of stromal VEGF.
@ast
Cross-species vascular endothe ...... contribution of stromal VEGF.
@en
prefLabel
Cross-species vascular endothe ...... contribution of stromal VEGF.
@ast
Cross-species vascular endothe ...... contribution of stromal VEGF.
@en
P2093
P921
P356
P1476
Cross-species vascular endothe ...... e contribution of stromal VEGF
@en
P2093
Chingwei V Lee
Franklin V Peale
Germaine Fuh
Hans-Peter Gerber
Johnny Gutierrez
Napoleone Ferrara
Wei-Ching Liang
Y Gloria Meng
P304
P356
10.1074/JBC.M508199200
P407
P50
P577
2005-11-07T00:00:00Z